Obutinib treatment for SLE phase IIb study achieves primary endpoint and is approved for episode artwork

EPISODE · Dec 14, 2025 · 1 MIN

Obutinib treatment for SLE phase IIb study achieves primary endpoint and is approved for

from DTnewswire · host DTnewswire

Smf5Yv7iSAZW7lGwgunC

NOW PLAYING

Obutinib treatment for SLE phase IIb study achieves primary endpoint and is approved for

0:00 1:51

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of DTnewswire?

This episode is 1 minute long.

When was this DTnewswire episode published?

This episode was published on December 14, 2025.

What is this episode about?

Smf5Yv7iSAZW7lGwgunC

Can I download this DTnewswire episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!